Epigenetic changes appear to be candidates as early stage biomarkers for Parkinson

NewsGuard 100/100 Score

Parkinson disease, a neurodegenerative disorder in which both genetic and environmental factors play important roles, has been associated with epigenetic changes (those molecular modifications that alter the behavior of genes without changing the DNA sequence). Because accurate diagnosis is not easy for this disease, scientists are continuously trying to identify early signs of the disease that enable treatment before major neurological damage occurs. In an article published in the October issue of Epigenetics, those epigenetic changes appear to be great candidates as early stage biomarkers for Parkinson Disease. Researchers from UCSD have now shown that a distinctive pattern of epigenetic modifications (in this case called DNA methylation) is observed in specific genes associated with the disease. Even more interesting, these changes could be easily analyzed in blood samples from patients, which appear to replicate the "epigenetic status" of brain tissue cells, potentially simplifying early diagnosis of the disease. The full open access report is available at the following link: https://www.landesbioscience.com/journals/epigenetics/article/25865/

Epigenetics is a multidisciplinary peer-reviewed journal that publishes original research and review articles covering the latest findings about epigenetic mechanisms and their role in diverse biological processes. Established in 1997, Landes Bioscience is an Austin, Texas-based publisher of biology research journals and books. For more information on Landes Bioscience, please visit http://www.landesbioscience.com/.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RNA editing using CRISPRs shows promise for genetic disease treatment